Anxiety Disorders Completed Phase 3 Trials for Risperidone (DB00734)

Also known as: Anxiety Disorder / Anxiety NOS

IndicationStatusPhase
DBCOND0027904 (Anxiety Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00086112Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.Treatment
NCT00277654Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety DisorderTreatment